Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients

CONCLUSION: The use of biologics or small molecules for patients with IBD who received organ transplants did not show a significant difference in safety outcomes. However, the possibility of severe infections must be considered.PMID:38653566 | DOI:10.3349/ymj.2023.0361

Source: Yonsei Medical Journal - April 23, 2024 Category: Universities & Medical Training Authors: Ga Hee Kim Minjun Kim Kyuwon Kim Jung-Bin Park Ji Eun Baek June Hwa Bae Seung Wook Hong Sung Wook Hwang Dong-Hoon Yang Byong Duk Ye Jeong-Sik Byeon Seung-Jae Myung Suk-Kyun Yang Sang Hyoung Park Source Type: research